On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

MuSK antibody positive adults and pediatric gMG patients aged 12 and older. FDA Approves New Treatment for Generalized ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

We also meet people living with myasthenia gravis, a neuromuscular autoimmune disease that can have devastating effects. And we learn about a new study on ‘stress bragging’ in the workplace.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

House: Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for IMAAVY (nipocalimab-aahu) ...

This milestone marks another significant advancement for the more than 100,000 people living with gMG in the U.S. gMG is a chronic autoimmune ... myasthenia gravis and all rare neuromuscular ...